Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

Keitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, Sara Horie, Akihiko Chida, Kai Tsugaru, Kazuhiro Togasaki, Kenta Kawasaki, Kenro Hirata, Hideyuki Hayashi, Yasuo Hamamoto, Takanori Kanai

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.

Original languageEnglish
Pages (from-to)2593-2603
Number of pages11
JournalFuture Oncology
Volume17
Issue number20
DOIs
Publication statusPublished - 2021 Jul

Keywords

  • Fine-Gray regression model
  • PD-1
  • Type I hypersensitivity reaction
  • immune checkpoint inhibitors
  • immune-related adverse events
  • risk factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data'. Together they form a unique fingerprint.

Cite this